Clinical Trial to Investigate the Efficacy and Safety of DWJ1351

Inclusion Criteria: * Subject who provided written informed consent to participate in this study * Healthy adult male subjects aged 19 to 50 years * Subjects whose body weight ≥ 55 kg and Body Mass Index(BMI) ≥ 18.0 kg/m2 and ≤ 27.0 kg/m2 * Subject who was judged to be healthy and suitable for the participation by the investigator based on screening test results Exclusion Criteria: * Subject who had a severe allergy or allergic reactions to the amlodipine, olmesartan, rosuvastatin or related drugs * Subjects who had a serious clinical illness that can impact fate of drugs absorption * Subject who shows vital signs with the number of systolic blood pressure of \>140 mmHg or \<100 mmHg, and the number of diastolic blood pressure of \>90mmHg or \<65mmHg * Subject who have experienced drug abuse * Subject who donates his blood (whole blood donation within last 2 months or plasma donation within last 1 month) * Subject who has taken other clinical or licensed medication from another clinical trial within an 3-month period prior to the first administration of the study medication